Exelixis Inc. | TalkMarkets

Latest Posts

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024

Article By: Zacks Investment Research

Saturday, March 9, 2024 4:00 PM EDT

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the year.

In this article: EXEL, EXAS, ASND, LEGN, MOR

Read

3 Attractive Medical Stocks To Buy After Earnings

Article By: Zacks Investment Research

Thursday, February 8, 2024 7:50 PM EDT

Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare stocks that investors will want to consider

In this article: MCK, EXEL, EHC

Read

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy

Article By: ChinaBio® Today

Saturday, September 16, 2023 12:59 PM EDT

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis.

In this article: SHPMF, EXEL, TSVT, SRNEQ

Read

This Biotech Looks Good With Increased M&A Activity

Article By: InvestorsAlley

Friday, May 20, 2022 3:49 AM EDT

Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.

In this article: ACAD, EXEL, XBI

Read